Article Details
Retrieved on: 2022-03-03 17:52:27
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Roche's new trial of gantenerumab, called SKYLINE, will enroll 1,200 people whose disease is confirmed by brain imaging or biomarkers in cerebrospinal ...
Article found on: www.biopharmadive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here